StockNews Upgrades BAT (NYSE:BTI) Stock Rating to Buy

BAT by 2FIRSTS.ai
Dec.06.2023
StockNews Upgrades BAT (NYSE:BTI) Stock Rating to Buy
StockNews, a US stock news website, has upgraded its rating for British American Tobacco (NYSE: BTI) from "hold" to "buy".

According to multiple sources, StockNews, a US stock news website, recently upgraded its stock rating of British American Tobacco (NYSE:BTI) from "hold" to "buy".

 

Several other stock research analysts have also weighed in on the company. Argus downgraded their rating from "buy" to "hold." Meanwhile, Morgan Stanley and Citigroup both initiated coverage of British American Tobacco on November 1st and September 25th, respectively, and both gave it a "buy" rating.

 

Two investment analysts have given a "hold" rating on the stock, while three have given a "buy" rating. According to MarketBeat's data, British American Tobacco currently has an average rating of "moderate buy".

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%
BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%
BlackRock increased its stake in KT&G to 5.01% after purchasing 68,646 shares, bringing total holdings to 5,914,169 shares and triggering Korea’s large-shareholding disclosure rules. KT&G shares climbed to an all-time intraday high of 153,900(about US$106.19) won and closed at a record 152,900(about US$105.50) won. KT&G is set to report earnings on Feb. 5, with consensus pointing to year-on-year growth in revenue and operating profit.
Jan.30 by 2FIRSTS.ai
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar said restricting vape flavour choices—potentially under the Tobacco and Vapes Bill—could disrupt established quitting behaviours and increase relapse risk among former smokers. An Opinium survey commissioned by the company reported fruit and sweet flavours have risen in popularity among adult vapers quitting smoking in Scotland, with 62% now using them most often to quit, up from 34% in December 2024.
Feb.28 by 2FIRSTS.ai
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
India has reaffirmed its 2019 ban on e-cigarettes and heated tobacco devices, effectively blocking Philip Morris International (PMI) from launching IQOS in the country despite years of lobbying. Together with Taiwan, China’s conditional opening of heated tobacco products, and Japan’s planned 2026 excise tax hikes, these moves highlight increasingly divergent national regulatory pathways—an external uncertainty shaping PMI’s smoke-free growth trajectory.
Feb.12
Malaysia anti-tobacco groups call for stronger enforcement as unregulated vapes remain on sale offline and online
Malaysia anti-tobacco groups call for stronger enforcement as unregulated vapes remain on sale offline and online
Anti-tobacco groups in Malaysia say the continued sale of unregulated vapes in physical stores and the online availability of vape devices underline the need for comprehensive enforcement.
Mar.02 by 2FIRSTS.ai
Ohio Supreme Court takes up appeal that could define state limits on illegal vape sales enforcement
Ohio Supreme Court takes up appeal that could define state limits on illegal vape sales enforcement
The Ohio Supreme Court has agreed to hear Attorney General Dave Yost’s appeal seeking to revive lawsuits against three Ohio vape retailers. Lower courts dismissed the cases, finding that federal law governs whether vaping products may be marketed and sold.
Mar.06 by 2FIRSTS.ai
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18